A QT/QTc Evaluation Study of TS-142 in Healthy Adult Subjects

NCT04873323 | Completed Phase 1

• 1 other identifier: TS142-209
• Study Type: interventional
• Target: 59
• Locations: 1 country
• Sites: 1

Brief Summary

A clinical study to evaluate the effects on QT/QTc Interval of TS-142 in Healthy Adult Subjects

Conditions

Healthy Subjects

Outcome Measures

Primary Outcomes (1)

• QTcF:QT-interval corrected by Fridericia corrections in Holter ECGs

  Difference (ΔΔQTc) in change from baseline (ΔQTc) in QTc interval at each time point in each group compared with the placebo group

  Up to 24 hours postdose during each period

Study Arms (4)

TS-142 10 mg

EXPERIMENTAL

TS-142 therapeutic dose oral tablet (low dose)

Drug: TS-142

TS-142 30 mg

EXPERIMENTAL

Description: TS-142 supratherapeutic dose oral tablet (high dose)

Drug: TS-142

Moxifloxacin 400 mg

EXPERIMENTAL

Moxifloxacin tablet

Drug: Moxifloxacin

Placebo

EXPERIMENTAL

Placebo oral tablet

Drug: Placebo

Interventions

TS-142 DRUG

Single dose of TS-142 10 mg or TS-142 30 mg in the morning under fasting in each period

TS-142 10 mg; TS-142 30 mg

Moxifloxacin DRUG

Single dose of moxifloxacin 400 mg in the morning under fasting in each period

Moxifloxacin 400 mg

Placebo DRUG

Single dose of TS-142 placebo in the morning under fasting in each period

Placebo

Eligibility Criteria

• Age: 20 Years - 39 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Japanese Males or females aged 20 years or older but less than 40 years at the time of informed consent
• those with a BMI of 18.5 in male (17.6 in female) or more and less than 25.0 and a body weight of 40.0 kg or more at screening test
• those whose pulse rate measured by standard 12-lead ECG is 50 beats/min or more but no more than 90 beats/min at screening test and at the time before administration of investigational drug in period 1
• those who are judged eligible to participate in the study by the principal investigator or sub-investigator based on the results of screening test and test conducted before administration of investigational drug in period 1. However, if who showed abnormal findings but not clinically significant, they can be enrolled in clinical trials based on comprehensive consideration of medical viewpoints by the principal investigator or subinvestigator.
• those who are able to receive the explanation before participating in the study, understand the content of the study, and provide written informed consent by the subjects themselves.

You may not qualify if:

• Subjects who have any disease and are not considered healthy subjects based on the medical judgment of the principal investigator or sub-investigator.
• Subjects with a medical history considered inappropriate for participation in the study, including respiratory, cardiovascular, gastrointestinal, hepatic, renal, urological, endocrine, metabolic, hematological, immune, skin, neurological, and psychiatric diseases.
• Subjects with a history of drug allergy or food allergy.
• Subjects with a history of hypersensitivity to moxifloxacin or other quinolone antimicrobials
• Subjects with risk factors or with a history of risk factors for aortic aneurysm, aortic dissection (such as Marfan syndrome)
• Subjects with significant allergic predisposition (such as asthma requiring medical treatment)
• Subjects with congenital disease, heart disease, or a history of heart disease
• Subjects with risk factors or with a history of risk factors for torsade de pointes (TdP) (heart failure, hypokalemia, family history of long QT syndrome, etc.)
• Subjects with a history of unconscious seizures suspected of involving TdP.
• Subjects with waveforms difficult to assess for QTc interval prolongation in standard 12-lead ECG at screening and the timing before administration of investigational product in period 1 (drift, electromyography contamination, T-wave geometry, marked sinus arrhythmia, frequent premature beats, etc.)
• Subjects with QTcF(Fridericia correction method) of at least 450 msec in men and at least 470 msec in women in standard-12-lead ECG at screening test and at the time before administration of investigational product in period 1.
• Subjects with suicidal ideation, suicide attempt on the Colombian Suicide Assessment Scale (C-SSRS) on Day-1 or a history of suicide attempt within the previous 5 years.

Sponsors & Collaborators

• Taisho Pharmaceutical Co., Ltd.: lead

Study Sites (1)

Taisho Pharmaceutical Co., Ltd selected site

Toshima-ku, Japan

Location

MeSH Terms

Interventions

TS-142; Moxifloxacin

Intervention Hierarchy (Ancestors)

Fluoroquinolones; 4-Quinolones; Quinolones; Quinolines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Study Officials

• Taisho Direcoter

  Taisho Pharmaceutical Co., Ltd.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 30, 2021
• First Posted: May 5, 2021
• Study Start: June 7, 2021
• Primary Completion: September 28, 2021
• Study Completion: September 28, 2021
• Last Updated: February 28, 2025

Record last verified: 2021-10

Data Sharing

• IPD Sharing: Will not share

Locations

JP (1)